Pasar al contenido principal

ALTERACIONES GENOMICAS Y EPIGENOMICAS EN LA EVOLUCION DE LINFOMAS AGRESIVOS. DIANAS PARA APLICACIONES CLINICAS.

RTI2018-094274-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma

  • Demajo, Santiago
  • Albero Gallego, Robert|||0000-0001-5527-0997
  • Clot, Guillem|||0000-0003-2588-7413
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Navarro, Alba|||0000-0002-4041-0974
  • Capdevila, Cristina
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Giné, Eva|||0000-0002-0532-1204
  • Pinyol, Magda
  • Jaffe, E.S.
  • Ott, German|||0000-0001-7990-6793
  • Staudt, L.M.
  • Rosenwald, Andreas|||0000-0001-7282-8374
  • Scott, D.W.
  • Rimsza, L.M.
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Bea, Sílvia|||0000-0001-7192-2385
  • Campo, Elias|||0000-0001-9850-9793
  • Jares, Pedro
Purpose: Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation leading to cyclin D1 overexpression. Cyclin D1 is a major cell-cycle regulator and also regulates transcription, but the impact of cyclin D1-mediated transcriptional dysregulation on MCL pathogenesis remains poorly understood. The aim of this study was to define a cyclin D1-dependent gene expression program and analyze its prognostic value. Experimental Design: We integrated genome-wide expression analysis of cyclin D1-silenced and overexpressing cells with cyclin D1 chromatin-binding profiles to identify a cyclin D1-dependent transcriptional program in MCL cells. We analyzed this gene program in two MCL series of peripheral blood samples (n ¼ 53) and lymphoid tissues (n ¼ 106) to determine its biological and clinical relevance. We then obtained a simplified signature of this program and evaluated a third series of peripheral blood MCL samples (n ¼ 81) by NanoString gene expression profiling to validate our findings. Results: We identified a cyclin D1-dependent transcriptional program composed of 295 genes that were mainly involved in cell-cycle control. The cyclin D1-dependent gene program was overexpressed in MCL tumors directly proportional to cyclin D1 levels. High expression of this program conferred an adverse prognosis with significant shorter overall survival of the patients. These observations were validated in an independent cohort of patients using a simplified 37-gene cyclin D1 signature. The cyclin D1-dependent transcriptional program was also present in multiple myeloma and breast tumors with cyclin D1 overexpression. Conclusions: We identified a cyclin D1-dependent transcriptional program that is overexpressed in MCL and predicts clinical outcome.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

  • Bastidas-Mora, Gabriela
  • Beà, Silvia
  • Navarro, Alba
  • Giné, Eva
  • Costa, Dolors
  • Delgado, Julio
  • Baumann, Tycho
  • Magnano, Laura
  • Rivas-Delgado, Alfredo
  • Villamor, Neus
  • Colomer, Dolors
  • Lopez-Guerra, Mónica
  • Rozman, María
  • Balagué, Olga
  • Martínez, Daniel
  • Baptista, Maria Joao
  • Escoda, Lourdes
  • Alcoceba, Miguel
  • Blanes, Margarita
  • Climent, Fina
  • Campo, Elías
  • Wotherspoon, Andrew
  • López-Guillermo, Armando
  • Matutes, Estella
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0·05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4·025, P = 0·05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3·89, P < 0·001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4·92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5·294, P = 0·016) and lack of CR (HR 2·67, P < 0·001)., This work was supported by grants from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (PI17/01061 to Sílvia Beà, PI19/00887 to Armando López-Guillermo), Fundacion AECC/CIBERONC (PROYE18020BEA to Sílvia Beà), and CIBERONC (CB16/12/00334 to Dolors Colomer, and CB16/12/00225 to Elías Campo), Generalitat de Catalunya Suport Grups de Recerca AGAUR, 2017-SGR-709 (to Sílvia Beà) 2017-SGR-1009 (to Dolors Colomer), 2017-SGR-1142 (to Elías Campo), Ministerio de Ciencia e Innovación (MCI) [Grant No. RTI2018-094274-B-I00 (to Elías Campo)] and the European Regional Development Fund ‘Una manera de fer Europa’. Elías Campo is an Academia Researcher of the ‘Institució Catalana de Recerca i Estudis Avançats’ (ICREA) of the Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

  • Giné, Eva
  • Cruz, Fátima de la
  • Jiménez-Ubieto, Ana
  • López Jiménez, Javier
  • García-Sancho, Alejandro Martín
  • Terol, María José
  • González-Barca, Eva
  • Casanova, María
  • Fuente, Adolfo de la
  • Marín-Niebla, Ana
  • Muntañola, Ana
  • González-López, Tomás J.
  • Aymerich, Marta
  • Setoain, Xavier
  • Cortés-Romera, Montserrat
  • Rotger, Amanda
  • Rodríguez, Sonia
  • Medina, Alejandro
  • García-Sanz, Ramón
  • Nadeu, Ferran
  • Beà, Silvia
  • Campo, Elías
  • López-Guillermo, Armando
[Puropose]: The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients., [Methods]: This is a multicenter single-arm, open-label, phase II study with a two-stage design conducted in 12 Spanish GELTAMO sites (ClinicalTrials.gov identifier: NCT02682641). Previously untreated MCL patients with indolent clinical forms defined by the following criteria were eligible: no disease-related symptoms, nonblastoid variants, Ki-67 < 30%, and largest tumor diameter ≤ 3 cm. Both leukemic non-nodal and nodal subtypes were recruited. Patients received ibrutinib 560 mg once daily and a total of eight doses of rituximab 375 mg/m2. Ibrutinib could be discontinued after 2 years in the case of sustained undetectable minimal residual disease (MRD). The primary end point was the complete response (CR) rate achieved after 12 cycles according to Lugano criteria., [Results]: Fifty patients with MCL (male 66%; median age 65 years) were enrolled. After 12 cycles of treatment, 42 (84%; 95% CI, 74 to 94) patients had an overall response, including 40 (80%; 95% CI, 69 to 91) with CR. Moreover, undetectable MRD in peripheral blood was achieved in 87% (95% CI, 77 to 97) of cases. At 2 years, 24 of 35 evaluable patients (69%) could discontinue ibrutinib because of undetectable MRD. Four patients had disease progression; three were non-nodal MCL and carried high genomic complexity and TP53 mutations at enrollment. No unexpected toxicity was seen except one patient with severe aplastic anemia., [Conclusion]: Frontline IR combination achieves a high rate of CRs and undetectable MRD in indolent clinical forms of MCL. Discontinuation seems appropriate in cases with undetectable MRD, except for TP53-mutated cases., The authors would like to thank the patients and their families, and study investigators and coordinators—among them, Carlos Grande, Lucia Palacios, and Silvia Ru´ız—for their contribution to the study. Partial support of biological and MRD studies was obtained from grants Instituto de Salud Carlos III (ISCIII) PI19/00887 (to A.L.-G. and E.G.) and PI17/ 01061 (to S.B.), Fundacio La Marat ´ o de TV3 grant 201904-30 (to S.B.), ´ Ministerio de Ciencia e Innovacion (MCI) RTI2018-094274-B-I00 (to ´E.C.), National Institutes of Health (NIH) 1P01CA229100 (to E.C.) and FEDER: European Regional Development Fund “Una manera de hacer Europa” (to E.C. and S.B.). A personal grant FEHH-Janssen 2021 to Alejandro Medina-Herrera from Fundacion Española de Hematología y Hemoterapia is acknowledged. E.C. is an ICREA Academia Researcher, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

  • Bastidas-Mora, Gabriela
  • Bea, Sílvia|||0000-0001-7192-2385
  • Navarro, Alba|||0000-0002-4041-0974
  • Giné, Eva|||0000-0002-0532-1204
  • Costa, Dolors|||0000-0002-8276-3292
  • Delgado, Julio|||0000-0002-5157-4376
  • Baumann, Tycho|||0000-0003-4421-0088
  • Magnano, Laura|||0000-0002-6928-8386
  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • Villamor, Neus|||0000-0001-6538-4111
  • Colomer, Dolors|||0000-0001-7486-8484
  • López Guerra, Mónica|||0000-0002-5545-0178
  • Rozman, Maria|||0000-0002-2641-1110
  • Balagué, Olga|||0000-0002-5099-3675
  • Martínez Hernández, Daniel|||0000-0001-7492-5311
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Blanes, Margarita
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • Wotherspoon, Andrew
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Matutes, Estella|||0000-0001-6745-7046
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0·05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4·025, P = 0·05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3·89, P < 0·001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4·92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5·294, P = 0·016) and lack of CR (HR 2·67, P < 0·001).